Diabetes Journal Submission Guide: Scope, Format, and Files

For an Original Article, the journal's current structure puts Research Design and Methods, Results, and Discussion at the center. Use that sequence to make the reasoning auditable:

1. State the unresolved physiology. Define the mechanism, cell type, tissue, pathway, or disease process at issue.
2. Choose evidence that can discriminate. Include controls or perturbations that separate the proposed explanation from plausible alternatives.
3. Show relevance across the appropriate level. Connect molecular evidence to physiology, pathology, or a human observation without overgeneralizing.
4. Bound the conclusion. Distinguish causal evidence, association, model-system inference, and clinical implication.

Methods should remain in the main manuscript rather than being moved to supplemental material simply to meet a word limit. That current instruction is a useful editorial signal: reviewers need the experimental and analytic path close to the result.

The official instructions specify a title page with author and affiliation details, corresponding-author contact information, word and display-item counts, and a short running title. Main text and tables are submitted in Microsoft Word format using the journal's current formatting instructions; figures and online supplemental files are uploaded separately.

The current instructions describe Article Highlights as complete sentences answering what is known, what question was asked, what was found, and what the findings imply. Treat them as a consistency test: if the highlights, abstract, and conclusion name different contributions, the manuscript is not ready.

Use the official Diabetes ScholarOne portal only after the package is reconciled. The ADA instructions, rather than a saved local checklist, control the current upload fields.

Diabetes does not promise a case-specific path or schedule for every manuscript. The useful stage model is:

• Administrative check: The office confirms the submission form, files, author record, and required declarations.
• Editorial assessment: An editor tests physiology or pathophysiology ownership and whether the evidence is ready for review.
• External review: Invited experts assess the mechanism, methods, reporting, and limits when the paper is sent out.
• Decision synthesis: The editor reconciles the reviews and identifies the next evidentiary or editorial action.

Manusights internal analysis identifies the journal's explicit exclusion language as the most useful routing signal across the official Diabetes instructions, the ADA policy page, and the separate Diabetes Care owner. Diabetes does not publish diabetes education or routine application of accepted therapeutic and diagnostic approaches. That is stronger than a generic scope list because it tells authors which apparently relevant papers are not owned here.

Source limitations: ADA guidance defines scope and submission requirements, but it does not provide a universal acceptance formula. Beyond official guidance, the mechanism-to-consequence audit below is Manusights judgment designed to expose a routing mismatch before formatting begins.

We convert that boundary into a physiology-dependency test. Write the paper's main conclusion, then remove every disease label. If the conclusion becomes a general molecular, cellular, or metabolic observation, the manuscript must show why diabetes physiology changes the mechanism or consequence. Next remove the mechanistic evidence. If the paper still reads as a care, outcomes, or epidemiology study, Diabetes Care or another clinical owner may be more accurate.

This is Manusights editorial analysis, not an ADA acceptance formula. It gives authors a falsifiable routing test instead of a generic checklist. When neither ADA owner is precise, use the journal directory after defining whether mechanism or clinical use is the manuscript's protagonist.

Concrete requirements worth checking twice

The current instructions say the title page needs a running title of fewer than 47 characters and spaces. They require Article Highlights of 75 to 100 words or fewer for Original Articles, Brief Reports, and Reviews. They state a 4,000-word main-text limit for print Original Articles while keeping necessary methodological and analysis detail available. The submission route is mc.manuscriptcentral.com/diabetes. Confirm these live before upload because ADA can revise forms and instructions.

Model relevance

Explain why the cell, tissue, animal, cohort, or intervention represents the disease question. State where the model does not represent human diabetes.

Terminology

Follow the journal's current terminology instructions. In particular, use “type 1 diabetes” and “type 2 diabetes” rather than turning “diabetic” into a noun or relying on unclear abbreviations.

Human and clinical evidence

For clinical trials, systematic reviews, meta-analyses, human-islet studies, or other regulated designs, use the applicable registration, reporting, ethics, and resource-sharing rules. Do not make a clinical recommendation from a design built only to establish mechanism.

Data responsibility

Make ownership, analysis responsibility, availability, and any restriction explicit. The person named as guarantor and the corresponding author should be able to reconcile the manuscript, portal, and supporting files.

Wrong ADA journal: The manuscript is primarily about care delivery, education, or an accepted diagnostic application rather than diabetes physiology.

Mechanism by association: The paper measures a pathway and an outcome but does not test whether the pathway explains the outcome.

Highlights overclaim: The required Article Highlights imply clinical change that the study design cannot support.

Administrative mismatch: Author order, forms, counts, disclosure language, figures, and portal fields do not agree.

The supplement escape: Essential design or analysis detail is moved out of the main methods to make the text shorter, even though the current instructions explicitly caution against using the supplement to circumvent the limit.